Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19

January 27, 2021 Auto Bot AbCellera, bamlanivimab, Clinical Trials, Eli Lilly, etesevimab, LY-CoV555, reports, results, Study 0

Shots:

  • The P-II/III BLAZE-1 trial involves assessing of Bamlanivimab + Etesevimab (2800 mg) vs PBO in 1035 patients recently diagnosed with COVID-19 in the ambulatory setting
  • The results demonstrated an 70% reduction in risk of COVID-19 related hospitalizations and deaths in high-risk patients and improvements in all 2EPs including reductions in viral load and accelerated symptom resolution
  • The data from the BLAZE-1 study are both compelling and entirely consistent with the interim data that were the basis for EUA of bamlanivimab (700mg) in the US, Canada, and EU for mild to mod. COVID-19 in patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 or hospitalization

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Catalio Capital Management

The post Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19 first appeared on PharmaShots.